Published in Nature on February 16, 1989
Principles of protein-protein interactions. Proc Natl Acad Sci U S A (1996) 14.51
Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc Natl Acad Sci U S A (1990) 8.23
Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci (1993) 7.90
Anatomy of protein pockets and cavities: measurement of binding site geometry and implications for ligand design. Protein Sci (1998) 7.03
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev (1993) 3.33
HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. Proc Natl Acad Sci U S A (2006) 3.30
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
Nucleocapsid zinc fingers detected in retroviruses: EXAFS studies of intact viruses and the solution-state structure of the nucleocapsid protein from HIV-1. Protein Sci (1992) 2.79
Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol (1991) 2.65
Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci (1998) 2.52
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol (1994) 2.26
Protein sequence comparisons show that the 'pseudoproteases' encoded by poxviruses and certain retroviruses belong to the deoxyuridine triphosphatase family. Nucleic Acids Res (1990) 2.24
Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol (1991) 2.23
Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother (1995) 2.21
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology (2012) 1.83
Protein crystallography for non-crystallographers, or how to get the best (but not more) from published macromolecular structures. FEBS J (2007) 1.70
Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.61
Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc Natl Acad Sci U S A (1990) 1.55
Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Natl Acad Sci U S A (1994) 1.50
The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol (2012) 1.50
Proteolytic processing of Ty3 proteins is required for transposition. J Virol (1993) 1.49
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol (1991) 1.48
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today (2006) 1.46
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity. J Virol (2004) 1.40
Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria. J Virol (1993) 1.37
X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci U S A (1990) 1.34
Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates. J Virol (1990) 1.33
Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1991) 1.33
Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol (2005) 1.28
Flavivirus enzyme-substrate interactions studied with chimeric proteinases: identification of an intragenic locus important for substrate recognition. J Virol (1991) 1.27
Incorporation of 12-methoxydodecanoate into the human immunodeficiency virus 1 gag polyprotein precursor inhibits its proteolytic processing and virus production in a chronically infected human lymphoid cell line. Proc Natl Acad Sci U S A (1991) 1.27
The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J Virol (2003) 1.25
Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci U S A (1991) 1.24
Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J Virol (1992) 1.21
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1993) 1.21
Specific peptide-activated proteolytic cleavage of Escherichia coli elongation factor Tu. Proc Natl Acad Sci U S A (1998) 1.20
Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses (2010) 1.20
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1995) 1.20
Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase. J Virol (1990) 1.19
Mass-dependent bond vibrational dynamics influence catalysis by HIV-1 protease. J Am Chem Soc (2011) 1.18
Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants. Proc Natl Acad Sci U S A (1997) 1.17
Human immunodeficiency virus protease inhibitor ritonavir inhibits cholesterol efflux from human macrophage-derived foam cells. Am J Pathol (2007) 1.17
Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci (1992) 1.17
Macrocyclic beta-sheet peptides that mimic protein quaternary structure through intermolecular beta-sheet interactions. J Am Chem Soc (2007) 1.14
Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling. Protein Sci (1992) 1.13
The role of medical structural genomics in discovering new drugs for infectious diseases. PLoS Comput Biol (2009) 1.11
Cauliflower mosaic virus produces an aspartic proteinase to cleave its polyproteins. EMBO J (1989) 1.10
Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci U S A (1995) 1.10
Biomolecularmodeling and simulation: a field coming of age. Q Rev Biophys (2011) 1.06
Point mutations and sequence variability in proteins: redistributions of preexisting populations. Proc Natl Acad Sci U S A (2001) 1.06
Isolation of mutants of human immunodeficiency virus protease based on the toxicity of the enzyme in Escherichia coli. Proc Natl Acad Sci U S A (1990) 1.04
Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of gag precursors and result in the release of noninfectious virus particles. J Virol (1996) 1.01
Protein crystallography for aspiring crystallographers or how to avoid pitfalls and traps in macromolecular structure determination. FEBS J (2013) 0.99
Joint X-ray/neutron crystallographic study of HIV-1 protease with clinical inhibitor amprenavir: insights for drug design. J Med Chem (2013) 0.99
Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active. J Virol (1992) 0.98
A look inside HIV resistance through retroviral protease interaction maps. PLoS Comput Biol (2007) 0.96
Active-site mobility in human immunodeficiency virus, type 1, protease as demonstrated by crystal structure of A28S mutant. Protein Sci (1998) 0.96
Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct Biol (2003) 0.95
Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem (2012) 0.94
Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis. Proc Natl Acad Sci U S A (1993) 0.94
Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors. J Comput Aided Mol Des (2003) 0.90
Inhibitor design by wrapping packing defects in HIV-1 proteins. Proc Natl Acad Sci U S A (2004) 0.89
Insights from atomic-resolution X-ray structures of chemically synthesized HIV-1 protease in complex with inhibitors. J Mol Biol (2007) 0.88
Web application for studying the free energy of binding and protonation states of protein-ligand complexes based on HINT. J Comput Aided Mol Des (2009) 0.87
Expression of soluble cloned porcine pepsinogen A in Escherichia coli. Biochem J (1996) 0.86
Challenges and opportunities for new protein crystallization strategies in structure-based drug design. Expert Opin Drug Discov (2010) 0.86
HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern. J Chem Theory Comput (2012) 0.86
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.85
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
Binding of novel fullerene inhibitors to HIV-1 protease: insight through molecular dynamics and molecular mechanics Poisson-Boltzmann surface area calculations. J Comput Aided Mol Des (2011) 0.84
Using specificity to strategically target proteases. Bioorg Med Chem (2008) 0.84
Transition states of native and drug-resistant HIV-1 protease are the same. Proc Natl Acad Sci U S A (2012) 0.84
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob Agents Chemother (1993) 0.84
Organic carbamates in drug design and medicinal chemistry. J Med Chem (2015) 0.83
Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation. J Mol Model (2009) 0.82
Computer-aided discovery of anti-HIV agents. Bioorg Med Chem (2016) 0.82
Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro. Med Sci Monit (2012) 0.82
Cellular cofactors of lentiviral integrase: from target validation to drug discovery. Mol Biol Int (2012) 0.81
The ins and outs of presenilin 1 membrane topology. Proc Natl Acad Sci U S A (2004) 0.81
Validating the vitality strategy for fighting drug resistance. Proteins (2012) 0.81
Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease. BMC Bioinformatics (2015) 0.80
Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach. Proc Natl Acad Sci U S A (1991) 0.80
HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytes. Int J Med Sci (2008) 0.80
Celebrating structural biology. Nat Struct Mol Biol (2011) 0.80
Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J Mol Model (2014) 0.80
Predicting relative binding affinities of non-peptide HIV protease inhibitors with free energy perturbation calculations. J Comput Aided Mol Des (1999) 0.80
The early years of retroviral protease crystal structures. Biopolymers (2010) 0.79
Efavirenz enhances HIV-1 gag processing at the plasma membrane through Gag-Pol dimerization. J Virol (2013) 0.79
Distributions of experimental protein structures on coarse-grained free energy landscapes. J Chem Phys (2015) 0.78
Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors. J Med Chem (2012) 0.78
Macromolecular Crystallographic Information File. Methods Enzymol (1997) 11.94
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (1986) 7.06
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature (1988) 5.56
cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A (1987) 4.61
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects. Proc Natl Acad Sci U S A (1986) 3.59
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem (1989) 3.51
Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A (1986) 3.11
Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem (1988) 3.10
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Yeast and mammalian ras proteins have conserved biochemical properties. Nature (1985) 2.85
Identification of residues required for ligand binding to the beta-adrenergic receptor. Proc Natl Acad Sci U S A (1987) 2.81
Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core. Nature (1987) 2.73
CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science (1987) 2.67
Purification of ras GTPase activating protein from bovine brain. Proc Natl Acad Sci U S A (1988) 2.41
Structural features required for ligand binding to the beta-adrenergic receptor. EMBO J (1987) 2.41
Structural basis of beta-adrenergic receptor function. FASEB J (1989) 2.27
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun (1988) 2.14
A C-terminal domain of GAP is sufficient to stimulate ras p21 GTPase activity. EMBO J (1989) 2.14
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. J Med Chem (1994) 2.07
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. J Biol Chem (1990) 1.95
Letter: The structure of saxitoxin. J Am Chem Soc (1975) 1.92
Purification and properties of thiol beta-lactamase. A mutant of pBR322 beta-lactamase in which the active site serine has been replaced with cysteine. J Biol Chem (1984) 1.88
Sequence of the gene encoding the human M1 muscarinic acetylcholine receptor. Nucleic Acids Res (1987) 1.80
Thiol-beta-lactamase: replacement of the active-site serine of RTEM beta-lactamase by a cysteine residue. Proc Natl Acad Sci U S A (1982) 1.74
Identification of guanine nucleotides bound to ras-encoded proteins in growing yeast cells. J Biol Chem (1987) 1.74
Regulatory function of the Saccharomyces cerevisiae RAS C-terminus. Mol Cell Biol (1987) 1.51
Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem (1994) 1.51
Structure and synthesis of moniliformin, a novel cyclobutane microbial toxin. J Am Chem Soc (1974) 1.50
Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme. Protein Sci (1995) 1.50
Structure of human neutrophil elastase in complex with a peptide chloromethyl ketone inhibitor at 1.84-A resolution. Proc Natl Acad Sci U S A (1989) 1.46
Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. Chem Biol (1998) 1.41
Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J Biol Chem (2001) 1.38
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease. Proc Natl Acad Sci U S A (1988) 1.36
Mutations that uncouple the beta-adrenergic receptor from Gs and increase agonist affinity. J Biol Chem (1987) 1.36
Ras interaction with the GTPase-activating protein (GAP). Proteins (1989) 1.35
Prostaglandin receptor EP(4) mediates the bone anabolic effects of PGE(2). Mol Pharmacol (2001) 1.35
Mycotoxins produced by Aspergillus fumigatus species isolated from molded silage. J Agric Food Chem (1977) 1.34
Letter: Tryptoquivaline and tryptoquivalone, two tremorgenic metabolites of aspergillus clavatus. J Am Chem Soc (1975) 1.32
Structure of inositol monophosphatase, the putative target of lithium therapy. Proc Natl Acad Sci U S A (1992) 1.32
Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J Biol Chem (1989) 1.28
Host cell factor requirement for hepatitis C virus enzyme maturation. Proc Natl Acad Sci U S A (2001) 1.27
Characterization of an active single polypeptide form of the human immunodeficiency virus type 1 protease. J Biol Chem (1990) 1.25
The herpesvirus proteases as targets for antiviral chemotherapy. Antivir Chem Chemother (2000) 1.21
An adenylate cyclase from Saccharomyces cerevisiae that is stimulated by RAS proteins with effector mutations. Mol Cell Biol (1988) 1.19
The carboxyl terminus of the hamster beta-adrenergic receptor expressed in mouse L cells is not required for receptor sequestration. Cell (1987) 1.19
A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem (1989) 1.15
Xenopus oocyte germinal-vesicle breakdown induced by [Val12]Ras is inhibited by a cytosol-localized Ras mutant. Proc Natl Acad Sci U S A (1989) 1.15
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A (1996) 1.14
New isomeric classes of topically active ocular hypotensive carbonic anhydrase inhibitors: 5-substituted thieno[2,3-b]thiophene-2-sulfonamides and 5-substituted thieno[3,2-b]thiophene-2-sulfonamides. J Med Chem (1991) 1.12
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. J Med Chem (1992) 1.10
Role of coenzyme in aminotransferase turnover. J Biol Chem (1977) 1.06
Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem (1989) 1.05
Affinity purification of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.05
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site. J Med Chem (1995) 1.05
Structure-function analysis of the beta-adrenergic receptor. Cold Spring Harb Symp Quant Biol (1988) 1.04
FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem (1993) 1.03
Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial. J Urol (1996) 1.03
Experience in 100 patients with an ileal low pressure bladder substitute combined with an afferent tubular isoperistaltic segment. J Urol (1995) 1.03
Dimerization and activation of the herpes simplex virus type 1 protease. J Biol Chem (1997) 1.02
The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology (1998) 1.01
L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. J Med Chem (1991) 1.00
The structure of human acidic fibroblast growth factor and its interaction with heparin. Arch Biochem Biophys (1991) 1.00
Structural studies of metal binding by inositol monophosphatase: evidence for two-metal ion catalysis. Biochemistry (1994) 1.00
Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration. J Biol Chem (1992) 0.99
Summary of 10 years' experience with an ileal low-pressure bladder substitute combined with an afferent tubular isoperistaltic segment. World J Urol (1996) 0.98
Decreased sensitivity in the membranous urethra after orthotopic ileal bladder substitute. J Urol (1999) 0.98
Site-directed mutagenesis of glutathione S-transferase YaYa. Important roles of tyrosine 9 and aspartic acid 101 in catalysis. J Biol Chem (1992) 0.97
Phosphinic acid inhibitors of D-alanyl-D-alanine ligase. J Med Chem (1988) 0.97
The NMR structure of the inhibited catalytic domain of human stromelysin-1. Nat Struct Biol (1994) 0.97
Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci (1994) 0.96
Structural analysis of inositol monophosphatase complexes with substrates. Biochemistry (1994) 0.96
Structure and function of retroviral proteases. Annu Rev Biophys Biophys Chem (1991) 0.96
HIV-1 protease inhibitors based on hydroxyethylene dipeptide isosteres: an investigation into the role of the P1' side chain on structure-activity. J Med Chem (1992) 0.96
Secondary structure and zinc ligation of human recombinant short-form stromelysin by multidimensional heteronuclear NMR. Biochemistry (1993) 0.95
Separation of the structural requirements for agonist-promoted activation and sequestration of the beta-adrenergic receptor. Mol Pharmacol (1990) 0.95
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligands. J Med Chem (1993) 0.93
Agonist-promoted sequestration of the beta 2-adrenergic receptor requires regions involved in functional coupling with Gs. Mol Pharmacol (1989) 0.92
Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem (1980) 0.92